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1. Introduction 
1.1. Pharmacognosy of Diabetes Mellitus 
Diabetes mellitus type II (T2DM) is a global public health crisis that threatens the economies 
of all nations, particularly developing countries. Fueled by rapid urbanization, nutrition 
transition, and increasingly sedentary lifestyles, the epidemic has grown in parallel with the 
worldwide rise in obesity. According to the International Diabetes Federation [1], diabetes 
affects at least 285 million people worldwide, and that number is expected to reach 438 
million by the year 2030, with two-thirds of all diabetes cases occurring in low- to middle-
income countries. The number of adults with impaired glucose tolerance will rise from 344 
million in 2010 to an estimated 472 million by 2030. Several factors contribute to accelerated 
diabetes epidemic, including the “normal-weight metabolically obese” phenotype; high 
prevalence of smoking and heavy alcohol use; high intake of refined carbohydrates (e.g., 
white rice); and dramatically decreased physical activity levels [2]. 
In spite of the tremendous progress in the management of diabetes using synthetic drugs, 
potential new and inexpensive treatments should be used to reduce the global morbidity 
and mortality, as most of the people with T2DM lives in areas of the world, where existing 
treatments are unavailable or are too expensive. It is well documented that insulin sensitivity 
and glucose tolerance can be modulated by use of traditional medicines that are mainly 
derived from plants [3-5]. Natural antidiabetic agents with fewer side effects from readily 
available medicinal plants offer great potential in the discovery of new antidiabetic drugs. 
Pharmacognosy (the study of the medicinal properties of materials of natural origin) has 
played an important role in the management of diabetes mellitus since ancient times. 
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Indeed, it has been estimated that more than 800 herbal or plant-derived products have been 
used for the management of T2DM across geographically and culturally diverse populations 
worldwide [6-9].  
World Health Organization (WHO) recommendations [10] on the use of alternative 
medicines for treating diabetes mellitus provide an impetus for research in this area. 
Currently, the focus of research includes discovering newer antidiabetic agents as well as 
isolating the active compounds from herbal sources that have been documented to have 
antidiabetic properties as have been described in ancient texts. The active components of a 
number of plant-derived antidiabetic compounds have been identified, and amongst these 
are flavonoids, alkaloids, glycosides, polysaccharides, peptidoglycans, hypoglycans, 
guanidine, steroids, carbohydrates, glycopeptides, terpenoids and amino acids. Potentially 
beneficial effects on the rate of food digestion, glucose transport, potentiation of insulin 
release, inhibition of insulin clearance, insulin-mimetic effects, reduced gluconeogenesis, 
and β-cell protection have been attributed to these agents [11].  
Type 2 diabetes (T2DM) is a disease characterized by a dual defect: 1) by insulin resistance 
which prevents cells from using insulin properly and 2) degrees of reduced pancreatic 
insulin secretion. It is a progressive disease that shows a consistent deterioration in glycemic 
control over time. While the pathophysiology and pathogenesis of the T2DM is not fully 
understood, it is clear that impaired glucose tolerance (IGT) often develops into T2DM.  
Interventions that may delay or prevent the progression of IGT to T2DM are desperately 
needed. Hyperlipidaemia is a secondary complication in diabetes and there is a growing 
interest in plants with both hypoglycaemic and hypolipidemic properties since they have a 
potential to be developed further for effective  treatment for diabetes specially associated 
with a hyperlipidaemic state. Since Artocarpus heterophyllus is traditionally used for 
management of diabetes mellitus, it may hold promise in this regard and warrants 
pharmacognostical, pharmacological and clinical studies to investigate the therapeutic 
potential of this plant in the treatment of T2DM. 
1.2. Overview of Artocarpus heterophyllus 
Artocarpus heterophyllus Lam (family Moraceae), commonly known as jakfruit is one of the 
most significant trees in tropical homegardens and perhaps the most widespread tree in the 
genus Artocarpus. It is a medium-size evergreen tree typically reaching 8–25 m (26–82 ft) in 
height with evergreen, alternate, glossy and leathery leaves to 22.5 cm (9 in) in length.  
Jackfruit's place of origin is believed to be indigenous to the rainforests of the Western 
Ghats. Today, it is cultivated at low elevations throughout India, Sri Lanka, Myanmar, 
southern China, Malaya, East Indies, Queensland, Mauritius, Kenya, Uganda and former 
Zanzibar, Pacific islands and Brazil [12]. 
Many parts of the plant including the bark, roots, leaves, and fruit are attributed with 
medicinal properties. It  is reported in Ayurveda (a traditional medicine system in Sri Lanka 
and India) to possess antibacterial, anti-inflammatory, antidiabetic, antioxidant and 
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immunomodulatory  properties. It is an important source of compounds like morin, 
dihydromorin, cynomacurin, artocarpin, isoartocarpin, cyloartocarpin, artocarpesin, 
oxydihydroartocarpesin, artocarpetin, norartocarpetin, cycloartinone, betulinic acid, 
artocarpanone and  heterophylol which have therapeutic properties [13]. 
The root is a remedy for skin diseases and asthma and the extract is taken in cases of fever 
and diarrhea. The ashes of the leaves, burned together with corn and coconut shells are used 
alone or mixed with coconut oil to heal ulcers. Mixed with vinegar, the latex promotes 
healing of abscesses, snakebite and glandular swellings. Heated leaves alone are placed on 
wounds and the bark is made into poultices. The seed starch is given to relieve biliousness 
and the roasted seeds are regarded as aphrodisiac. In Chinese medicine the pulp and seeds 
are considered tonic and nutritious [12]. 
 
Figure 1. Mature leaves of A. heterophyllus 
1.3. Aim of the chapter 
Alternative systems of medicine such as Ayurveda is widely used in Sri Lanka and India. 
In Ayurveda diabetes falls under the term Madhumeha [14]. Various types of herbal 
preparations such as decoctions (boiled extracts), Swaras (expressed juices), Asav-Arisht 
(fermented juices), and powders have been used for the treatment of Madhumeha [14]. 
Hot water extracts of A. heterophyllus leaves are used in the treatment of T2DM by 
traditional medical practioners in Sri lanka and India [15,16]. This traditional claim was first 
scientifically validated by the investigations carried out by Fernando et. al [17] which 
demonstrated the hypoglycaemic potential of the leaf extract. This preliminary work has 
been followed by many other studies which have provided insights into the efficacy, safety, 
mechanisms of action and the presence of other bioactivities of therapeutic potential in A. 
heterophyllus leaves. This chapter is based on the investigations carried out by 
Chackrewarthy et al [18] to evaluate the hypoglycaemic and hypolipidaemic potential of an 
ethylacetate fraction of A. heterophyllus leaves using a normal and streptozotocin induced 
diabetic rat models.   
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2. Phytochemical screening and standardized extraction 
Plant extracts used in traditional medicine are chemically complex and may contain one or 
more structurally related active compounds that produce a combined effect. Standardization 
and phytochemical screening are essential measurements of ensuring quality control of 
herbal drugs. 
Phytochemical screening of the aqueous extract of the leaves has revealed the presence of a 
range of polyphenols such as flavanoids, anthocyanins, tannins and polysaccharides as 
constituents [19].  In a more recent study of the aqueous extract of leaves, the presence of 
proteins, saponins, sterols, glycosides and lipids have been revealed in addition to the 
compounds mentioned [20]. A total ash value of  0.84%, acid insoluble ash value of 0.12% 
and water soluble ash value of 0.35% on dry weight basis have been reported for the 
aqueous extract of the leaves. 
The purpose of standardized extraction procedures of plant crude extracts  is to attain the 
therapeutically desired fractions and to eliminate unwanted material by treatment with  
selective solvents. In general, the solvent system used for the extraction plays a significant 
role in the solubility of the active principles of plant materials which in turn influence the 
bioactivities of the fractions [21].  
Plant crude extracts usually contain large amounts of carbohydrates and/or lipoidal material 
and the concentration of the phenolics in the crude extract may be low [22]. To concentrate 
and obtain polyphenol rich fractions before analysis, strategies including sequential 
extraction is commonly used. Sequential extraction with solvents of increasing polarity; eg: 
hexane, dichloromethane (DCM), ethyl acetate, methanol and water leads to initial 
fractionation of constituents of plant materials based mainly on their nature of polarity and 
with minimal chemical damage [23]. Based on this procedure an initial fractionation of the 
constituents of  A. heterophyllus leaves was carried out in the present study. Generally, waxy 
and lipoid substances are extracted into hexane and DCM and polyphenols are extracted 
into more polar solvents such as ethylacetate, methanol and water. In particular, methanol 
has been generally found to be more efficient in extraction of sugars, organic acids and 
lower molecular weight polyphenols while the higher molecular weight flavanols are better 
extracted with ethylacetate [24-27]. In recent studies, the phytochemical screening of the 
ethylactate fraction of A. heterophyllus leaves and bark has revealed the presence of 
flavanoids in high content. [28,29]. All fractions were evaporated to dryness and the 
residues stored at -40C until use.    
3. Hypoglycaemic activity of A.heterophyllus leaves 
3.1. Effects on fasting blood glucose levels 
The hypoglycemic potential of fractions separated from A. heterophyllus leaves by sequential 
fractionation, were tested using a normoglycaemic rat model. Male Wistar rats were fasted 
overnight, devided into groups and each group was treated with a different fraction by oral 
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administration at a dose equivalent to 50 mg/kg body weight. The ethylacetate (EA) fraction 
and the water fraction were found to exert the highest hypoglycemic effects compared to the 
controls treated with distilled water (Fig 2). The reduction in fasting blood glucose levels at 
+2 hr mediated by ethylacetate and water fractions were 42.5% and 28.7% respectively. This 
demonstrates that both these fractions contain the active principals mediating the 
hypoglycaemic effect in varying proportions.  Methanol fraction also had significant activity 
similar to the aqueous fraction, but the initial hypoglycaemic effect (+1 hr) was more 
prominent in the aqueous fraction (30% vs 16%). In experiments carried out by Fernando et 
al [17] with the crude extract of A. heterophyllus leaves, the fasting blood glucose levels of 
normoglycaemic rats were reduced by 24% at +3hr. However, this reduction was obtained 
with a higher dose of 10g/kg body weight of A. hetertophyllus starting material. Further, 
purification and fractionation results in an enhancement of bioactivity by eliminating the 
unwanted material which could exert inhibitory effects on the bioactivity of interest. Since 
the ethylacetate fraction has been shown to contain a high content of flavanoids by 
phyotochemical screening [19,28,29], the hypoglycaemic activity of this fraction could be 
attributed to a high molecular weight flavanoid which has a higher solubility in ethylacetate 
than in water.  
 
Figure 2. The effects of ethylacetate (EtAc), methanol and water fractions of A.heterophyllus leaves on 
fasting blood glucose levels of normoglycaemic rats. Data expressed as % change in blood glucose level. 
Each point is the mean of six determinations. 
3.2. Effects on glucose tolerance  
Impaired glucose tolerance is a pre-diabetic state which may precede T2DM. The oral 
glucose tolerance test (OGTT) was used as a screening method for acute antihyperglycemic 
activity since the results give the overall effect of the test material on the handling of an 
external glucose load [30]. 
Glucose tolerance studies with normoglycaemic rats, receiving the ethylacetate fraction 
showed a significant improvement in their ability to utilize the external glucose load 
compared to the control group (Fig. 3). This was dose dependant, and a dosage of 20mg/kg 
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was found to be more effective than 10 mg/kg. Compared with the controls, the reduction in 
blood glucose concentration at 2 hr post glucose administration was 18.9% and 26.4% for 
dosages of 10 mg/kg and 20 mg/kg respectively (Table 1). Reductions in blood glucose levels 
were statistically significant between the control curve and test curves at all time intervals. 
In similar experiments a higher dose of 150mg/kg of the ethylacetate fraction had resulted in 
a 36.9% reduction in blood glucose at 2 hr post glucose administration [28].  
Effects of the hot water extract of A. heterophyllus leaves on glucose tolerance of healthy 
individuals and maturity onset diabetic patients have been investigated by Fernando et al 
[31]. Oral administration of the hot water extract equivalent to a dose of 20g/kg starting 
material, one hour before the glucose load of 50 g, resulted in a significant improvement in 
the glucose tolerance of normal subjects and in the diabetic patients compared to the 
controls receiving distilled water. These data provide confirmatory evidence for the 
presence of antidiabetic principals in the leaf extract and validate its use in the treatment of 
diabetes by traditional medical practitioners.   
 
 
Mean serum glucose concentration 
(mg/dl) % reduction in serum 
glucose compared to control 
Fasting 2 hrs post glucose
Control 95.1  ±  4.4 169.5 ±  3.6  
EA fraction (10 mg/kg) 96.5  ±  2.3 137.3 ±  2.7 18.9* 
EA fraction (20 mg/kg) 98.6  ±  3.5 124.8 ±  4.2 26.4* 
Gibenclamide (0.6 mg/kg) 98.3  ±  1.9 108.5  ± 2.9 35.9* 
*Significantly different (p<0.05) compared to control 
Table 1. Effect of ethylacetate fraction on glucose tolerance 
 
Figure 3. The effects of ethylacetate (EtAc) fraction of A.heterophyllus leaves at doses of 10 mg/kg and 20 
mg/kg bodyweight, on glucose tolerance of normoglycaemic rats. Data expressed as % change in blood 
glucose level. Each point is the mean of six determinations. 
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3.3. Animal models of diabetes mellitus 
Non-insulin-dependent forms of diabetes can be produced by administration of a low dose 
of Streptozotocin (STZ) or alloxan [32]. These kinds of models of diabetes are considered a 
screening step in the search for drugs for the treatment of diabetes [33].  
Streptozotocin (STZ) is an antibiotic derived from Streptomyces achromogenes and structurally 
is a glucosamine derivative of nitrosourea. Its structural similarity to glucose allows it to 
enter the pancreatic beta-cell via a glucose transporter-GLUT-2 and causes alkylation of 
deoxyribonucleic acid (DNA). Furthermore, STZ induces activation of poly-adenosine 
diphosphate  ribosylation and nitric oxide release. As a result of STZ action, pancreatic beta-
cells are destroyed by necrosis [34]. The diabetes induced by STZ is associated with 
polydipsia and loss in body weight [35]. Although high-dose STZ severely impairs insulin 
secretion mimicking type 1 diabetes, low-dose STZ has been known to induce a mild 
impairment of insulin secretion which generate an impairment in glucose metabolism 
leading to glucose intolerance and mild, moderate or severe hyperglycaemia [36, 37]. 
Further, it also affects the lipid metabolism which leads to hyperlipidaemia which closely 
mimic the natural course of pathogenesis of T2DM [36-39]. The potential problem with STZ 
is that its toxic effects are not restricted to pancreatic beta-cells since it may cause renal 
injury [40], oxidative stress, inflammation and endothelial dysfunction [41]. Despite its 
widespread use, there is a wide variability in the extent of diabetes depending on species, 
strain and age limiting the predictability of its effects and precautions should be taken when 
trying to extrapolate the findings to the clinical practice [42,43]. 
3.4. Effect of chronic administration of ethylacetate extract on fasting blood 
glucose levels of sterptozotocin-induced diabetic rats  
Diabetes was induced in male Wistar rats by a single intravenous injection of freshly 
prepared STZ solution (in 0.1 M citrate buffer pH = 4.5) at a dose of 60 mg/kg body weight. 
The efficacy of antidiabetic plant materials may vary with time and investigating the effects 
of sub chronic or chronic administration is a necessary requirement in evaluating the profile 
of long term effects of herbal extracts [44]. 
Chronic administration (Table 2) of the EA fraction to rats at dose of 20 mg/kg for five 
consecutive weeks  caused a significant fall (P < 0.05) in the fasting blood sugar levels of 
diabetic rats when compared with diabetic controls which did not receive the ethylacetate 
fraction. This is evident in the second week itself and the reduction in the fasting blood 
sugar in the ethylacetate fraction treated rats (22.8%) was fairly comparable to that produced 
by the reference drug glibenclamide (32.2%) during the same time period. As in the 
glibenclamide-treated rats, in rats receiving the ethylacetate fraction also, the fall in the 
blood sugar level continued progressively till the end of the fifth week. A maximum fall of 
39.1%  and 55.7% were seen for for the ethylacetate fraction and glibenclamide respectively 
at the end of the fifth week. In a more recent study, chronic administration of the aqueous 
extract of A. heterophyllus leaves to streptozotocin induced diabetic rats has shown similar 
results [20]. There was a 51% decrease in fasting blood sugar level for a dose of 250 mg/kg in 
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diabetic rats at the end of the first week when compared with diabetic controls. The fall in 
fasting blood sugar has continued progressively during the period of treatment with the 
extract. In another study conducted by Mohana Priya et al [29] using a similar protocol, 
chronic administration of an ethylacetate fraction of the A. heterophyllus bark extract has 
resulted in a maximum fall of fasting blood glucose level by 27.5% for a dose of 400mg/kg 
body weight.   
Glibenclamide being a standard drug for the treatment of T2DM, stimulates insulin 
secretion from pancreatic β-cells.[45] Therefore, it may be suggested that stimulation of 
insulin release from the still functioning β-cells by active principles in ethylacetate fraction 
may be one of the mechanisms by which this fraction mediates its hypoglycemic effect, as 
proposed for some other plant extracts.[46,47] Further, components of the ethylacetate 
fraction as proposed by Gomes et al.[48] with reference to Camellia sinensis (black tea), may 
be able to generate β-cells of the pancreas or protect the intact β-cells from further 
deterioration so that they may remain active and continue to produce insulin. 
Histopathological analysis of pancreas of streptozotocin induced diabetic rats chronically 
treated with an ethylacetate fraction of A. heterophyllus bark extract has revealed initial 
stages of regenerating islet cells with loss of degenerative features when compared with 
diabetic controls in which progressive β cell vacuolation, occasional apoptotic cells with 
vascular congestion and fibrous tissue infilteration was observed in the pancreas. All the 
above findings provide the biochemical basis for the use of A. heterophyllus leaves in the 
management of patients with diabetes and confirms its role as a traditional antidiabetic 
remedy.  
 
Groups Post STZ 2 weeks 4 weeks 5 weeks 
Normal control 98.4± 2.9 90.6± 5.7 91.6 ± 4.8 92.7 ± 6.6 
Diabetic control 254.3± 2.5 245.5± 6.6a 250.0 ± 3.9a 253.4 ± 6.3 a 
Diabetic + EA fraction  
(20 mg kg-1 bw) 
252.8±11.9 189.4± 5.1b 160.1±11.0 b 154.2± 11.1 b 
Diabetic + Glibenclamide  
(0.6 mg kg-1 bw) 
235.2 ± 8.3 166.4 ± 4.8 c 126.6 ± 9.2 c 112.3 ± 7.5 c 
Serum glucose levels in mg dl-1. Significantly different (p<0.05) compared to normal controls a , compared to diabetic 
controls b  , EA treated diabetic rats c 
Table 2. Serum glucose levels in STZ-induced diabetic rats after prolonged treatment with ethylacetate 
fraction  
4. Effect of chronic administration of ethylacetate extract on body 
weights and hyperlipidaemia associated with diabetes  
Hyperlipidemia is a metabolic complication of both clinical and experimental diabetes.[49] 
Insulin plays a major role in lipid metabolism apart from its regulation of carbohydrate 
metabolism. Insulin increases the receptor mediated removal of LDL cholesterol and 
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activates lipoprotein lipase for the hydrolysis of triacylglycerols in lipoproteins. Therefore, 
reduced activity if insulin in diabetes causes hypercholesterolaemia and 
hypertriglyceridaemia. This is cleary demonstrated in the diabetic controls of the present 
study by the increased levels of serum total cholesterol (TC) and triacylglycerols (TG) in 
diabetic rats when compared to normal control rats (Table 3).  
 
Groups 
Total 
Cholesterol(mg/dl) 
Triglycerides 
(mg/dl ) 
Body 
weight (g) 
Normal control 78.2 ± 3.8 102.2 ± 2.3 201.0 ± 8.5 
Diabetic control 127.9 ± 3.2 a 199.8 ± 6.2 a 172.1± 5.5 
Diabetic + EA fraction  
(20 mg kg-1 bw) 
98.5 ± 4.3 b 119.0 ± 2.5 b 190.4 ± 1.2 
Diabetic + Glibenclamide  
(0.6 mg kg-1 bw) 
87.4 ± 3.2 c 116.8 ± 1.3 c 196.5 ± 3.3 
Significantly different (p<0.05) compared to normal controls a ,compared to diabetic controls b ,EA treated diabetic 
ratsc  
Table 3. Serum total cholesterol, triglyceride levels and body weight in STZ-induced diabetic rats after 
five weeks of treatment with ethylacetate fraction 
Alterations in the lipid profiles and body weights of STZ-induced diabetic rats are 
summarized in Table 3. Treatment of diabetic rats with the ethylacetate fraction resulted in a 
significant fall (P <0.05) in the levels of both total cholesterol (TC) and TGs compared to 
diabetic controls. The fall in serum TG levels (40%) was more marked than that of 
cholesterol levels (23%).  This effect on diabetic hypertriglyceridemia in ethylacetate fraction 
treated rats could be due to improved glycemic control. The improved glycemic control by 
sulfonylureas accompanied by decreased serum very low density lipoprotein (VLDL) and 
TG levels has already been reported.[50] The reduction in cholesterol levels in diabetic test 
rats could be due to an inhibitory effect of the active principles on enzymes of cholesterol 
biosynthesis[51,52] and/or due to the enhanced activity of enzymes involved in bile acid 
synthesis and its excretion [53]. Further, stimulation of insulin secretion in response to the 
treatment with the extract could increase the uptake of low density lipoprotein (LDL) 
cholesterol by extrahepatic tissues contributing to the cholesterol lowering effects of the 
ethylacetate fraction. However, to obtain confirmatory evidence of these views, further 
studies on the effects of the ethylacetate fraction on LDL and high density lipoprotein (HDL) 
cholesterol levels and their clearance need to be investigated. A high fat intake and 
increased levels of free fatty acids in circulation have been implicated in the development of 
insulin resistance.[54,55] Based on these observations, it could be speculated that the EA 
fraction mediated reduction in circulating levels of TGs may also help to ameliorate insulin 
resistance in diabetic rats and thereby stimulate glucose utilization by peripheral tissues.[56] 
In a more recent study the chronic administration of  aqueous extract of A. heterophyllus 
leaves have been shown to reduce the serum total cholesterol level and improve the HDL 
 Glucose Tolerance 216 
levels and the body weight in streptozotocin induced diabetic rats [20]. Similar effects have 
been shown for the ethyacetate fraction of A. heterophyllus bark on diabetic rats [29].  
Loss of body weight in diabetic rats is due to increased muscle wasting and loss of tissue 
proteins [57]. As evident from Table 3, the ethylacetate fraction had an improving effect on the 
BW (11%) of diabetic rats, which was restored to near normal levels.  This may be a reflection 
of improved health resulting from the effects of the ethylacetate fraction on insulin release. 
5. Toxicity 
The use of herbal medicines for the treatment or prevention of a variety of diseases has 
increased markedly. Herbal medicines are believed to be benign and  not cause severe 
toxicity. This coupled with lower costs compared with conventional medications is the 
major attraction  to these treatments. The active ingredients of plant extracts are chemicals 
similar to those in purified medications, and they have the same potential to cause serious 
side effects. The usefulness of any drug depends not only on its therapeutic efficacy but also 
on its lack of toxicity or adverse side effects. Therefore, toxicological investigations have to 
be carried out before any drug can be considered as safe. This is specially important in the 
case of antidiabetic drugs, which have to be administered over a relatively long period of 
time to obtain their pharmacological potency.  
Hot water extracts of A. heterophyllus leaves have been used from ancient times as a 
treatment for diabetes in traditional medicine in Sri Lanka and no evidence has been 
reported of any toxicity or adverse side effects. However, this requires scientific validation 
with toxicological studies. An in vivo study using Sprague Dawley rats carried out by 
Fernando and Thabrew [58] has demonstrated that an aqueous extract of  mature leaves of 
A. heterophyllus exerted no adverse effects even after daily administration for 30 days, as 
assessed by effects on (a) liver function, (b) haematological parameters such as haemoglobin 
concentration, red blood cell count, white blood cell count and packed cell volume, (c) 
reproductive ability of experimental animals and (d) histology of body organs (heart, liver, 
lung,kidney, intestine and pancreas). Investigations carried out by Chandrika et al [28] also 
have revealed that the chronic administration of the ethylacetate fraction of A. heterophyllus 
leaves to normoglycaemic rats over a period of twelve weeks at a dose of 50 mg/kg body 
weight failed to bring any overt signs of toxicity such as salivation, diarrhea, lacrymation, 
postural abnormalities or behavioural changes. No significant differences had been 
observed in the liver function tests and the histology of various body organs between the 
test and the control groups. A. heterophyllus leaf extract can therefore be considered to be free 
of any major toxic compounds or adverse effects.  
6. Mechanism of action 
Antidiabetic activity of plant extracts is mainly due to their ability to restore the function of 
the pancreatic tissue by causing an increase in insulin secretion or inhibit the intestinal 
absorption of glucose or by facilitation of the insulin dependant process. 
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In investigations carried out by Fernando & Thabrew [59] to investigate the mechanism of 
action, the hypoglycaemic activity of the aqueous extract of A. heterophyllus leaves has been 
attributed to an extra pancreatic effect, resulting from the inhibition or destruction of 
insulinase by the constituents of the leaf extract. Improved glycaemic control is achieved by 
prolonging the half life of insulin. Further, no effects of the extract have been observed on 
the intestinal glucose absorption in experimental rats. 
In vitro investigations carried out by Kotowaroo et al [60], on the mechanism of action have 
revealed that aqueous leaf extract of A. heterophyllus significantly (p < 0.05) inhibited α-
amylase activity in rat plasma. Further, enzyme kinetic studies using the Michaelis-Menten 
and Lineweaver-Burk equations have established that the aqueous leaf extract of A. 
heterophyllus behaved as a competitive inhibitor. Results from this study  indicated that A. 
heterophyllus could act as a ‘starch blocker’ thereby reducing post-prandial glucose peaks. 
However, this finding does not agree with the fact that the leaf extract significantly 
improves the glucose tolerance by improving the ability to handle an external glucose load, 
which has been consistently demonstrated in both animal and human studies conducted so 
far. However, the possibility exists, that the leaf extract could exert its hypoglycaemic effects 
through more than one mechanism.  
Furthermore, avialable evidence indicates that the active principals mediating the 
antidiabetic effect in A. heterophyllus leaves to be flavanoids. There is evidence that 
flavonoids, can increase the viability of beta-cells exposed to STZ or other oxidative stress 
conditions and improve beta-cell function [61-64]. Increased oxidative stress due either to 
fasting or postprandial hyperglycemia is accepted as a participant in increased beta-cell 
damage contributing to the development and progression of diabetes [65]. There is also 
evidence that the antioxidant defense system is under-expressed in pancreatic cells [66] and 
flavonoid-rich extracts administration to diabetic animal models has been shown to increase 
expression of enzymes like catalase and superoxide dismutase as well as glutathione 
peroxidase system [67, 68]. Therefore, there is a strong possibility of a pancreatic mechanism 
either by induction of insulin secretion or by recovery of beta-cell mass through which the 
hypoglycaemic activity of the leaf extract could be exerted. However, further research is 
necessary to elucidate the mechanism(s) of action. 
7. Conclusions 
An ethylacetate fraction of A. heterophyllus leaf extract exerts stong hypoglycaemic activity in 
both normoglycaemic and diabetic rats. Chronic administration of the ethylacetate fraction 
to STZ-induced diabetic rats resulted in a significant improvement in the hyperlipidaemia 
associated with diabetes leading to a significant lowering of serum total cholesterol and 
triglycerides. The effects of the improved glycaemic control was evident in the improvement 
of body weights in diabetic rats under chronic treatment with the ethylacetate fraction. 
Isolation and characterization of the active principals in the ethylacetate fraction followed by 
further pharmacological and clinical studies would provide with a novel herbal drug for 
T2DM therapy.     
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